Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

Delayed Quote. Delayed  - 05/06 10:02:31 pm
53.6 USD   -0.91%
05/05DJMARKET SNAPSHOT : S&P 500, Dow End Little Changed Ahead Of Jobs Repo..
05/05DJMARKET SNAPSHOT : U.S. Stocks Try To Avoid 3-day Slide A Day Ahead O..
05/05DJMARKET SNAPSHOT : U.S. Stocks Slump As Investors Adopt Cautious Stan..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

US Judge Upholds Validity Of Merck's Vytorin Patent

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/28/2012 | 12:29am CEST

--Judge rules U.S. patent for Vytorin and Zetia is valid and enforceable

--Mylan had challenged patent in bid to sell generic Vytorin and Zetia

--Merck patent due to expire in April 2017

(Adds statement from Merck, additional details.)

 
   By Peter Loftus 
   Of  
 

A federal judge has upheld the validity of a U.S. patent covering Merck & Co.'s (>> Merck & Co., Inc.) cholesterol-lowering drugs Vytorin and Zetia, which could stave off competing generic copies for several years.

In an opinion released Friday, U.S. District Judge Jose Linares in federal court in Newark, N.J., said the patent for was valid and enforceable. The patent covers ezetimibe, an active ingredient in both Zetia and Vytorin.

Merck, based in Whitehouse Station, N.J., said the U.S. patent for Vytorin and Zetia is due to expire in April 2017.

"The court appropriately ruled that the patent for Zetia and Vytorin in the U.S. is valid and enforceable," Bruce N. Kuhlik, executive vice president and general counsel of Merck, said in a press release.

Mylan Inc. (MYL) had applied for U.S. Food and Drug Administration approval to sell generic versions of Vytorin and Zetia before the patent expired, arguing that the patent was invalid and unenforceable.

Merck filed a patent-infringement lawsuit against Mylan in late 2009, seeking to block Mylan's plan to sell generic Vytorin, and in 2010 sued to block Mylan from selling generic Zetia. A trial was held in December 2011, leading to Judge Linares's opinion Friday.

Merck said the court also issued an injunction blocking the approval of Mylan's generic versions until the expiration of the patent.

A Mylan spokeswoman couldn't immediately be reached for comment.

Earlier Friday, Merck reported first-quarter Vytorin sales of $444 million and Zetia sales of $614 million.

Merck previously reached a settlement of patent litigation for Zetia with generics manufacturer Glenmark Pharmaceuticals. The pact will allow Glenmark to sell generic Zetia in December 2016, subject to final regulatory approval.

-By Peter Loftus, Dow Jones Newswires; 215-982-5581; peter.loftus@dowjones.com

Stocks mentioned in the article : Merck & Co., Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news on MERCK & CO., INC.
05/05DJMARKET SNAPSHOT : S&P 500, Dow End Little Changed Ahead Of Jobs Report; Nasdaq L..
05/05DJMARKET SNAPSHOT : U.S. Stocks Try To Avoid 3-day Slide A Day Ahead Of Jobs Repor..
05/05DJMARKET SNAPSHOT : U.S. Stocks Slump As Investors Adopt Cautious Stance
05/05DJMARKET SNAPSHOT : S&P 500, Dow End Little Changed Ahead Of Jobs Report; Nasdaq L..
05/05DJMARKET SNAPSHOT : U.S. Stocks Turn Negative As Oil Futures Pare Gains
05/05 MERCK : Reports Outline Bisphosphonates Findings from Merck & Company (Effects o..
05/05 MERCK : Sanford Heisler Wins Certification Victory in $250 Million Sex Discrimin..
05/05 DOW ANALYST MOVES : Mrk
05/05DJMARKET SNAPSHOT : U.S. Stocks Move Higher, Boosted By Oil's Gains
05/05DJMERCK : Revenue Falls on Generic Competition, Currency -- 2nd Update
Advertisement
News chart
Full-screen chart
Income Statement Evolution
More Financials